Therapeutic intervention of LRRK2 kinase inhibitors in Vps35 p.D620N Parkinsonism
Objective: To explore the therapeutic potential of LRRK2 kinase inhibitors in a Vps35 p.D620N mouse model of Parkinsonsim. Background: The discovery of a missense mutation, Vps35 p.D620N…Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) ‘non-responders’ patients who switched from placebo (PLC) or entacapone (ENT) to OPC…Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with or without baseline presence of dyskinesia (BPDys). Background: OPC, a…Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data
Objective: To assess the real-world safety profile of Gocovri® (amantadine) extended release capsules one year post-launch. Background: Gocovri received FDA approval in August 2017 for…Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson’s disease
Objective: Verification of the previously reported association between chronic use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson’s disease (PD),…Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy
Objective: Few reports describe experience with treatment of Parkinson's disease [PD] during pregnancy. About 5% of the population with PD are young onset (onset prior…Subacute Encephalopathy with Pimavanserin Treatment in Parkinson Disease
Objective: To report 3 cases of drug-induced encephalopathy in patients treated with pimavanserin (PVN) for Parkinson disease (PD) related psychosis (PDP). Background: Quetiapine and clozapine,…Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease duration on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 34
- Next Page »